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Summary
Selection Criteria
The investigators conducted a systematic search of PubMed, Web of Knowledge, and the 
Cochrane library from January 1, 1966 through January 20, 2010 using the search terms 
“oral mucosal lesion screening” and “oral lesions.” Additional articles were identified from 
other sources, such as reference lists and journals' Web sites. Data from screening and 
observational studies and randomized controlled trials published in English were considered. 
Studies were selected if they met the following criteria: (1) included histologic evaluation 
from biopsied lesions that were clinically detected, including some studies that used both 
clinical oral examinations and adjunctive techniques; (2) involved patients who sought care 
at either primary care medical or dental practices, were referred to a clinic because they had 
an oral mucosal disease, or received cancer therapy at a cancer treatment center; and (3) 
included patients who had either primary oral mucosal lesions or recurrent second oral 
malignancies not limited by stage or grade.
Key Study Factor
The authors conducted a systematic review and meta-analysis of studies assessing the 
effectiveness of clinical oral examinations (COEs) in predicting oral dysplasia or oral 
squamous cell carcinoma (OSCC). Quality of the studies was assessed using the Quality 
Assessment of Diagnostic Accuracy Studies (QUADAS) tool, which is an evidenced-based 
quality assessment tool used in systematic reviews of diagnostic accuracy studies.1 
QUADAS consists of 14 questions or criteria to which the possible responses are “yes,” 
“no,” or “unknown.” This tool was used to evaluate the quality of the studies, using criteria 
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such as representativeness of the study samples, eligibility criteria, study withdrawals, and 
whether patients received index testing (clinical oral examinations) and reference testing 
(gold standard test [biopsy]). QUADAS does not create an overall quality score but can be 
used to distinguish between high- and low-quality studies. The authors also used five of the 
QUADAS criteria to assess the level of the risk of bias (high, medium, and low).
Main Outcome Measure
The primary outcome measure was a histologic confirmation of dysplasia or OSCC in an 
oral mucosal lesion submitted for biopsy. For each study, investigators reported that they 
calculated the sensitivity, specificity, positive predictive value, negative predictive value, 
positive likelihood ratio (PLR), negative likelihood ratio (NLR), diagnostic odds ratio 
(DOR), and other measures of accuracy. The authors stated that because “clinically normal 
mucosa would not have been biopsied, 0.5 was added to all cells of the data analysis table to 
calculate the specificity.” (DOR is the odds of disease in test positives relative to the odds of 
disease in test negatives).2 PLRs and NLRs state how many times more likely a patient is to 
have or not to have a disease given a particular test result.3 PLRs above 5.0 and NLRs below 
0.2 give strong diagnostic evidence,4 while a value of 1.0 indicates that the diagnostic test 
provides no information on the probability of disease.
An overall meta-analysis was conducted for studies that met the inclusion criteria. Pooled 
summary measures for all studies combined were calculated for each statistical parameter. A 
random-effects model was used for the meta-analysis to account for inter-study variability. 
Heterogeneity between studies was assessed using the Cochran Q test and the inconsistency 
index, I2, which describes the percentage of total variation across studies that is due to 
heterogeneity rather than chance.5 (Heterogeneity is a measure of the inconsistency or 
variability between studies and can impact the generalizability of study results.) The authors 
also assessed publication bias.
Main Results
Twenty-four observational studies met the inclusion criteria. The studies, which were 
published between 1997 and 2011, involved 7079 patients with an overall sample of 1956 
patients who had lesions biopsied and histologically examined. Using QUADAS, the authors 
estimated that for two-thirds of the studies the risk of bias was low, and for one third, the 
risk was medium. No studies were determined to be at high risk for bias. The sensitivity, 
0.93 (95% CI: 0.91-0.94), of the COE was high, indicating that the COE identified dysplasia 
or OSCC when disease was truly present (small number of false negatives). The specificity, 
0.31 (95% CI: 0.28-0.34), was low, indicating that COE was poor in ruling out disease when 
disease was not present (large number of false positives). In this study, PLRs and NLRs 
were poor, indicating a relatively low ability of the COE to estimate the likelihood of 
disease in an individual. Similarly, the overall DOR, which can range from zero to infinity, 
was low (6.1; 95% CI: 2.1-17.60), suggesting that the COE was ineffective as a diagnostic 
method in predicting oral dysplasia or OSCC. Heterogeneity between studies was high, as 
indicated by the high I2 scores and corresponding P-values (all = 0.01), likely reflecting 
differences in patient populations and selection criteria. No publication bias was found.
Cleveland and Robison Page 2














The authors used sensitivity, specificity, and other parameters to evaluate the COE as a 
diagnostic test. They concluded that diagnosis of oral dysplasia or OSCC based on a COE 
alone correlates poorly with the histological results from a biopsy. This discrepancy may be 
explained by the similarity in appearance of benign and dysplastic oral mucosal lesions, 
expertise of examiners, and variations in diagnoses of pathologists. The authors voiced 
concern about the potential for false negatives, in which disease is present but not detected 
and treated. They also voiced concern about the high number of false positives, which may 
lead to unnecessary worry for those told they might have pathology. The authors supported 
the development of more sensitive and specific adjunctive techniques to improve the 
accuracy of clinical detection and diagnosis of oral dysplasia and OSCC.6,7
Commentary and Analysis
Systematic reviews of diagnostic and screening tests are fundamentally similar to other 
types of systematic reviews, but they differ in the criteria used to assess the quality of 
studies, the potential for bias, and the statistical methods used to combine results.3,8 The 
purpose of this meta-analysis was to evaluate the effectiveness of the COE in predicting the 
histologic diagnosis (biopsy) of dysplasia or OSCC. However, while the COE can identify 
potentially malignant lesions, it also can identify other abnormalities that may need a biopsy 
and treatment.9 The authors often referred to the COE as a diagnostic test, when in fact it is 
a screening test. Screening tests are intended to cast a broad net in capturing almost 
everyone in an asymptomatic population who has the disease.8 Although some areas of the 
mouth are difficult to visualize (e.g., ventral surface of the tongue and floor of the mouth), 
one would expect a high sensitivity (i.e., few false negatives) for areas that are clearly 
visible. Therefore a useful screening test is one that can effectively rule out disease among 
those who test negative.10 However, because oral cancer is such a rare disease,11 it is 
reasonable to expect a high number of false positive results compared to diseases that are 
more common. In contrast, a diagnostic test determines whether disease is actually present.3 
In this study, the diagnostic test was the gold standard, biopsy, which should be adept at 
ruling in or detecting disease and should have a high specificity (i.e., few false positives).
In this analysis, the authors, however, included only persons with test-positive COEs 
involving detected or suspected lesions that had been referred for biopsy (n = 7079) and who 
actually had the biopsy conducted (n = 1956). These lesions were subsequently determined 
by histology to have or not to have true disease; however, the authors do not provide these 
numbers. Persons identified by COE to have clinically normal mucosa (test negatives) 
would not have been referred for a biopsy and were not included in the study sample. 
Because these patients were not followed to determine who remained disease-free or 
developed disease, we have no information about true negatives or false negatives. In 
addition, we have no information about persons who tested positive on COE, but did not 
proceed to the next step or were found on subsequent examination to have a lesion that did 
not require a biopsy (false positives). To account, in part, for the lack of information, the 
authors indicate that they added 0.5 in the cells for true negatives and false positives in order 
to calculate specificity. However, the authors did not specify the statistical methodology that 
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allows for this type of substitution. The pooled summary estimates for the indicators 
assessing the accuracy of the COE in identifying oral dysplasia or OSCC, therefore, could 
not be directly measured in this meta-analysis, so reported values for sensitivity, specificity, 
PLR, NLR, and DOR for this meta-analysis may not be valid.
The transparency of the analysis would be improved with the addition of relevant findings 
from each included study. These findings would include the sample size along with 
estimates (or assumptions in the absence of data) used to determine the number (percent) 
that were true positive (TP), false negative (FP), true negative (TN), and false positive (FP) 
and selected indicators. For example, it's unclear how the authors estimated sensitivity when 
they have no information on the percent of persons with a false negative test. In addition, 
while it could have been possible to examine the percent of persons with a positive 
screening test (i.e., COE) who were found on biopsy to have dysplasia or malignancy (i.e., 
positive predictive value), the total number of patients with a positive COE, not just those 
who had a biopsy, would be needed.
The degree of heterogeneity across the studies was significant, as indicated by the p-values 
of the I2 scores (p = 0.01). In such cases, the degree of heterogeneity may be so large that it 
may be inappropriate to pool the performance of individual study parameters. When such 
heterogeneity across studies exists, it is difficult to draw conclusions about the summary test 
of specificity and the generalizability of results.
The authors used the QUADUS tool to evaluate the quality of the studies. The QUADUS 
tool includes 14 criteria to assess study quality, and the authors used five of the criteria to 
assign a level for the potential risk for bias (low, medium, or high) to each study.1 In 
reviewing the results of the QUADAS tool for the 24 studies, it is the opinion of these 
reviewers that the level of bias and heterogeneity among the studies appeared higher than 
was reported by the authors. For example, for the first QUADAS criteria, “Was the spectrum 
of patients representative of the patients who will receive the test in practice?” the answer 
was “no” for 21 of 24 studies (87.5%). For a third of the studies, the selection criteria were 
not clearly described. Execution of the reference test (biopsy) was not described in detail to 
permit replication in 29.2% of studies. More importantly, for four of the studies, neither the 
whole sample nor a random selection of the sample appeared to have received the reference 
or gold standard biopsy, which the authors indicated was a condition for exclusion. In 
addition, the authors of this analysis did not describe how they used five of the QUADAS 
criteria to determine that a study was at low (70.8%), medium (29.2%), or high risk (0.0%) 
for bias. We suggest that future systematic reviews evaluating the effectiveness of methods 
to predict oral dysplasia or OSCC use the revised QUADUS-2 tool, which allows for more 
transparent rating of bias and applicability of primary diagnostic accuracy studies.12
Oral cancer screening is defined by the American Dental Association (ADA) “as the process 
by which an asymptomatic patient is evaluated to determine if he/she is ‘likely’ or ‘unlikely’ 
to have a potentially malignant or malignant lesion.9 In a dental setting, the act of 
“screening” occurs when a patient reports for care and the practitioner obtains that patient's 
health history to assess risk, followed by the performance of a visual and tactile examination 
… to detect any oral abnormality.”9 However, for a COE to be considered an effective 
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screening test for oral cancer, early diagnosis and treatment would have to show an impact 
on the course of the disease. At this point, the evidence is sparse regarding the effectiveness 
of COEs (or more accurately, oral cancer screening) in detecting potentially malignant or 
oral malignant lesions or for improving morbidity or mortality.9,13 A nine-year randomized 
controlled trial provided some evidence that visual examination may have helped reduce 
death rates in certain high-risk patients, such as tobacco and heavy alcohol users.14 Based on 
this evidence, the American Dental Association in 2010 encouraged practitioners to “remain 
alert for signs of potentially malignant lesions or early stage cancers while performing 
routine visual and tactile examinations,” particularly among tobacco and alcohol users.9 Due 
to biases in the study, however, the U.S. Clinical Preventive Services Task Force concluded 
in 2004 and again in a recent draft Recommendation Statement that the evidence was 
insufficient to recommend for or against primary care providers routinely screening adults 
for oral cancer15 and a recent Cochrane review found no evidence that visual oral 
examinations reduced death rates.16
In addition to the COE, the majority of studies in this systematic review used an adjunctive 
method, such as to-luidine blue and autofluorescence, in predicting dysplasia or OSCC 
among patients screening positive for suspected lesions. The authors suggest that the use of 
adjunctive applications to highlight such lesions may increase the accuracy of clinical 
diagnosis and diagnostic yield. However, the ADA, in their review of the evidence found 
that there is insufficient evidence that the commercially available devices based on tissue 
reflectance and auto fluorescence improve the detection of potentially malignant lesions 
beyond that of a conventional visual and tactile examination.9
The most definitive measure of the effectiveness of COE as a screening test would be a 
comparison of cause specific mortality rates among asymptomatic persons whose disease 
was picked up by the COE and those whose diagnosis was related to the development of 
symptoms. Because of factors related to costs, ethics and feasibility, such studies are not 
likely to be carried out. Current research shows promising developments in the use 
biomarkers, such as salivary proteins and messenger RNAs, to discriminate patients with 
oral squamous cell carcinomas from healthy subjects.17 However, until these technologies 
are validated in large clinical trials, the COE remains the primary screening test to detect 
potentially malignant and malignant lesions.
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